Skip to main content
SpringerLink
Log in

Macrolide Antibacterials

Drug Interactions of Clinical Significance

  • Review Article
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Macrolide antibiotics can interact adversely with commonly used drugs, usually by altering metabolism due to complex formation and inhibition of cytochrome P-450 IIIA4 (CYP3A4) in the liver and enterocytes. In addition, pharmacokinetic drug interactions with macrolides can result from their antibiotic effect on microorganisms of the enteric flora, and through enhanced gastric emptying due to a motilin-like effect.

Macrolides may be classified into 3 different groups according to their affinity for CYP3A4, and thus their propensity to cause pharmacokinetic drug interactions. Troleandomycin, erythromycin and its prodrugs decrease drug metabolism and may produce drug interactions (group 1). Others, including clarithromycin, flurithromycin, midecamycin, midecamycin acetate (miocamycin; ponsinomycin), josamycin and roxithromycin (group 2) rarely cause interactions. Azithromycin, dirithromycin, rikamycin and spiramycin (group 3) do not inactivate CYP3A4 and do not engender these adverse effects.

Drug interactions with carbamazepine, cyclosporin, terfenadine, astemizole and theophylline represent the most frequently encountered interactions with macrolide antibiotics. If the combination of a macrolide and one of these compounds cannot be avoided, serum concentrations of concurrently administered drugs should be monitored and patients observed for signs of toxicity.

Rare interactions and those of dubious clinical importance are those with alfentanil and sufentanil, antacids and Cimetidine, oral anticoagulants, bromocriptine, clozapine, oral contraceptive steroids, digoxin, disopyramide, ergot alkaloids, felodipine, glibenclamide (glyburide), levodopa/carbidopa, lovastatin, methylprednisolone, phenazone (antipyrine), phenytoin, rifabutin and rifampicin (rifampin), triazolam and midazolam, valproic acid (sodium valproate) and zidovudine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kirst HA. New macrolides: expanded horizons for an old class of antibiotics. J Antimicrob Chemother 1991; 28: 787–90

    PubMed  CAS  Google Scholar 

  2. Fernandez PB. The macrolide revival: thirty-five years after erythromycin. Antimicrob Newslett 1987; 4: 25–33

    Google Scholar 

  3. Kirst HA, Sides GD. New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrob Agents Chemother 1989a; 33: 1413–8

    PubMed  CAS  Google Scholar 

  4. Kirst HA, Sides GD. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother 1989b; 33: 1419–22

    PubMed  CAS  Google Scholar 

  5. Peters DH, Clissold SP. Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 42(1): 117–64

    Google Scholar 

  6. Peters DH, Friedel HA, McTavish D. Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992; 44(5): 750–99

    PubMed  CAS  Google Scholar 

  7. von Rosenstiel NA, Adam D. Makrolidantibiotika. Arzneimitteltherapie. 1995, in press

  8. Young RA, Gonzalez JP, Sorkin EM. Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1989; 37: 8–41

    PubMed  CAS  Google Scholar 

  9. Carver PL. Clinically relevant drug interactions and adverse effects of antimicrobial agents. Curr Opin Infect Dis 1991; 4: 749–56

    Google Scholar 

  10. Descotes J, Andre P, Evreux JC. Pharmacokinetic drug interactions with macrolide antibiotics. J Antimicrob Chemother 1985; 15: 659–64

    PubMed  CAS  Google Scholar 

  11. Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450–82

    PubMed  CAS  Google Scholar 

  12. Periti P, Mazzei T, Mini E, et al. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23: 106–31

    PubMed  CAS  Google Scholar 

  13. Rodvold KA, Piscitelli SC. New oral macrolide and fluoroquinolone antibiotics: an overview of pharmacokinetics, interactions, and safety. Clin Infect Dis 1993; 17Suppl. 1: 192–9

    Google Scholar 

  14. Franklin MR. Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes. Pharmacol Ther 1977; 2: 227–45

    CAS  Google Scholar 

  15. George J, Farrell GC. Role of human hepatic cytochromes P450 in drug metabolism and toxicity. Aust N Z J Med 1991; 21: 356–62

    PubMed  CAS  Google Scholar 

  16. Larrey D, Funck-Brentano C, Breil P, et al. Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem Pharmacol 1983a; 32: 1063–8

    PubMed  CAS  Google Scholar 

  17. Larrey D, Tinel M, Pessayre D. Formation of inactive cytochrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats. Biochem Pharmacol 1983b; 32: 1487–93

    PubMed  CAS  Google Scholar 

  18. Lindstrom TD, Hanssen BR, Wrighton SA. Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrob Agents Chemother 1993; 37: 269

    Google Scholar 

  19. Miura T, Iwasaki A, Komory M, et al. Decrease in a constitutive form of cytochrome P-450 by macrolide antibiotics. J Antimicob Chemother 1989; 24: 551–9

    CAS  Google Scholar 

  20. Murray M. P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 1992; 23: 132–46

    PubMed  CAS  Google Scholar 

  21. Paire M, Lavarenne J. Interactions medicamenteuses avec les macrolides sur l’activite des microsomes hepatiques. Pathol Biol 1982; 30: 535–8

    PubMed  CAS  Google Scholar 

  22. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 1–21

    PubMed  CAS  Google Scholar 

  23. Hebert MF, Roberts JP, Prueksaritanont R, et al. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52: 454–7

    Google Scholar 

  24. Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. Identification of rifampin-inducible P450 IIIA4 (CYP 3A4) in human small bowel enterocytes. J Clin Invest 1992; 90: 1871–8

    PubMed  CAS  Google Scholar 

  25. Watkins PB, Wrighton SA, Shuetz EG, et al. Identification of glucocorticoid inducible cytochrome P450 in intestinal mucosa of rats and humans. J Clin Invest 1987; 80: 1029–36

    PubMed  CAS  Google Scholar 

  26. Watkins PB. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin N Am 1992; 21: 511–26

    CAS  Google Scholar 

  27. Park BK, Kitteringham NR. Assessment of enzyme induction and enzyme inhibition in humans: toxicologic implications. Xenobiotica 1990; 20: 1171–85

    PubMed  CAS  Google Scholar 

  28. Pessayre D. Effects of macrolide antibiotics on drug metabolism in rats and humans. Int J Clin Pharm Res 1983; III(6): 449–58

    Google Scholar 

  29. Pessayre D, Larrey D, Funk-Brentano C, et al. Drug interactions and hepatic toxicity produced by some macrolide antibiotics. J Antimicrob Chemother 1985; 16Suppl. H: 181–94

    PubMed  CAS  Google Scholar 

  30. Delaforge M, Sartori E, Mansuy D. Effects of roxithromycin on rat hepatic P-450 cytochromes: comparison with troleandomycin and erythromycin. Br J Clin Pract 1988; 42Suppl. 55: 67–9

    Google Scholar 

  31. Gascon MP, Dayer P. Comparative effects of macrolide antibiotics on liver monooxygenases. Clin Pharmacol Ther 1991a; 49: 158

    Google Scholar 

  32. Tinel M, Descatoire V, Larrey D, et al. Effects of clarithromycin on cytochrome P-450: comparison with other macrolides. J Pharmacol Exp Ther 1989; 250: 746–51

    PubMed  CAS  Google Scholar 

  33. Delaforge M, Jaouen M, Mansuy D. Dual effects of macrolide antibiotics on rat liver cytochrome P-450 induction and formation of metabolite-complexes: a structure activity relationship. Biochem Pharmacol 1983; 32: 2309–18

    PubMed  CAS  Google Scholar 

  34. Baciewicz AM. Carbamazepine drug interactions. Ther Drug Monit 1986; 8: 305–17

    PubMed  CAS  Google Scholar 

  35. Berrettini WH. A case of erythromycin-induced carbamazepine toxicity. J Clin Psychiatry 1986; 47: 147

    PubMed  CAS  Google Scholar 

  36. Carranco E, Kareus J, Co S, et al. Carbamazepine toxicity induced by concurrent erythromycin therapy. Arch Neurol 1985; 42: 187–8

    PubMed  CAS  Google Scholar 

  37. Goulden KJ, Camfield P, Dooley JM, et al. Severe carbamazepine intoxication after coadministration of erythromycin. J Pediatr 1986; 109: 135–8

    PubMed  CAS  Google Scholar 

  38. Hedrick R, William F, Morin R, et al. Carbamazepine-erythromycin interaction leading to carbamazepine toxicity in four epileptic children. Ther Drug Monit 1983; 5: 405–7

    PubMed  CAS  Google Scholar 

  39. Jaster PJ, Abbas D. Erythromycin-carbamazepine interaction. Neurology 1986; 36: 594–5

    PubMed  CAS  Google Scholar 

  40. Kessler JM. Erythromycin-carbamazepine interaction [letter]. S Afr Med J 1985; 67: 1038

    PubMed  CAS  Google Scholar 

  41. Loiseau P, Guyot M, Pautrizel B, et al. Carbamazepine intoxication caused by the interaction of carbamazepine-erythromycin [letter]. Presse Med 1985; 14: 162

    PubMed  CAS  Google Scholar 

  42. Straughan J. Erythromycin-carbamazepine interaction? [letter] S Afr Med J 1982; 61: 420–1

    PubMed  CAS  Google Scholar 

  43. Turner PV, Renton KW. The interaction between carbamazepine and erythromycin. Can J Physiol Pharmacol 1989; 67: 582–6

    PubMed  CAS  Google Scholar 

  44. Vajda FJ, Blandin PF. Carbamazepine-erythromycin base interaction [letter]. Med J Aust 1984; 140: 81

    PubMed  CAS  Google Scholar 

  45. Woody RC, Kearns GL, Bolyard KJ. Carbamazepine intoxication following the use of erythromycin in children. Pediatr Infect Dis J 1987; 6: 578–9

    PubMed  CAS  Google Scholar 

  46. Wroblewski BA, Singer WD, Whyte J. Carbamazepine-erythromycin interaction — case studies and clinical significance. JAMA 1986; 255: 1165–7

    PubMed  CAS  Google Scholar 

  47. Zitelli BJ, Howie DL, Altman H, et al. Erythromycin-induced drug interactions: an illustrative case and review of the literature. Clin Pediatr 1987; 26: 117–9

    CAS  Google Scholar 

  48. Barzaghi N, Gatti G, Crema F, et al. Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite. Br J Clin Pharmacol 1987; 24: 836–8

    PubMed  CAS  Google Scholar 

  49. McNab AJ, Robinson JL, Adderly RJ, et al. Heart block secondary to erythromycin-induced carbamazepine toxicity. Clin Pharmacol Ther 1987; 33: 460–4

    Google Scholar 

  50. Wong YY, Ludden TM, Bell RD. Effect of erythromycin on carbamazepine kinetics. Clin Pharmacol Ther 1983; 33. 460–4

    PubMed  CAS  Google Scholar 

  51. Mitsch RA. Carbamazepine toxicity precipitated by intravenous erythromycin. DICP Ann Pharmacother 1989; 23: 878–9

    CAS  Google Scholar 

  52. McNab AJ, Birch P, Macready J. Carbamazepine poisoning in children. Pediatr Emerg Care 1993; 9: 195–8

    Google Scholar 

  53. De Castro FJ. Carbamazepine: a fatal interaction. Am J Dis Child 1992; 146: 496

    Google Scholar 

  54. Viani F, Claris-Appiani A, Rossi LN. Severe hepatorenal failure in a child receiving carbamazepine and erythromycin. Eur J Pediatr 1992; 151: 715

    PubMed  CAS  Google Scholar 

  55. Albani F, Riva R, Baruzzi A. Clarithromycin-carbamazepine interaction: a case report. Epilepsia 1993; 34: 161–2

    PubMed  CAS  Google Scholar 

  56. Richens AS, Chu SY, Sennello LT, et al. Effect of multiple doses of clarithromycin on the pharmacokinetics of carbamazepine [abstract 760]. In: Program and Abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1990 Oct 23: Atlanta, GA. Washington, DC: American Society for Microbiology, 1990: 213

    Google Scholar 

  57. Barzaghi N, Gatti G, Crema F, et al. Effect of flurithromycin, a new macrolide antibiotic, on carbamazepine disposition in normal subjects. Int J Clin Pharmacol Res 1988; 8: 101–5

    PubMed  CAS  Google Scholar 

  58. Albin H, Vincon G, Pehourcq F, et al. Influence de la josamycine sur la pharmacocinetique de la carbamazepine. Therapie 1982; 37: 151–7

    PubMed  CAS  Google Scholar 

  59. Torregrosa JV, Campistol JM, Franco A. Interaction of josamycin with cyclosporin A. Nephron 1993; 65: 476–7

    PubMed  CAS  Google Scholar 

  60. Vincon G, Albin H, Demotes-Mainard F, et al. Effects of josamycin on carbamazepine kinetics. Eur J Clin Pharmacol 1987; 32: 312–3

    Google Scholar 

  61. Couet W, Istin B, Seniuta P, et al. Effect of ponsinomycin on cyclosporin pharmacokinetics. Eur J Clin Pharmacol 1990a; 39: 165–7

    PubMed  CAS  Google Scholar 

  62. Dravet C, Mesdjian E, Cenraud B, et al. Interaction between carbamazepine and triacetyloleandomycin. Lancet 1977; 1: 810–1

    PubMed  CAS  Google Scholar 

  63. Mesdijan E, Dravet C, Cenraud B, et al. Carbamazepine intoxication due to triacetyloleandomycin administration in epileptic patients. Epilepsia 1980; 21: 489–96

    Google Scholar 

  64. Raperport WG, Dewland PM, Muirhead DC, et al. Lack of interaction between azithromycin and carbamazepine. Br J Clin Pharmacol 1992; 30: 551P

    Google Scholar 

  65. Saint-Salvi B, Tremblay D, Surjus A, et al. A study of the interaction of roxithromycin with theophylline and carbamazepine. J Antimicrob Chemother 1987; 20Suppl. B: 121–9

    PubMed  CAS  Google Scholar 

  66. Chan GL, Sinnott JT, Emmanuel PJ. Drug interactions with cyclosporine: focus on antimicrobial agents. Clin Transplant 1992; 6: 141–53

    Google Scholar 

  67. Krombach T, Fischer V, Mayer UA. Cyclosporine metabolism in human liver: identification of a cytochrome p-450 3 gene family as the major cyclosporine-metabolizing enzyme explaining interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630–5

    Google Scholar 

  68. Freeman DJ, Martell R, Carruthers SG, et al. Cyclosporin-erythromycin interaction in normal subjects. Br J Clin Pharmacol 1987; 23: 776–8

    PubMed  CAS  Google Scholar 

  69. Jensen CWB, Flechner SM, van Buren CT, et al. Exacerbation of cyclosporin toxicity by concomitant administration of erythromycin. Transplantation 1987; 43: 263–70

    PubMed  CAS  Google Scholar 

  70. Vereerstraeten P, Thiry P, Kinnaer P, et al. Influence of erythromycin on cyclosporine pharmacokinetics. Transplantation 1987; 44: 155–6

    PubMed  CAS  Google Scholar 

  71. Wadhwa NK, Schroeder TJ, O’Flaherty E, et al. Interaction between erythromycin and cyclosporine in a kidney and pancreas allograft recipient. Ther Drug Monit 1987; 9: 123–5

    PubMed  CAS  Google Scholar 

  72. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (Part I). Clin Pharmacokinet 1990a; 19: 319–32

    PubMed  CAS  Google Scholar 

  73. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (Part II). Clin Pharmacokinet 1990b; 19: 400–15

    PubMed  CAS  Google Scholar 

  74. Aoki FY, Yatscoff R, Jeffrey J, et al. Effects of erythromycin on cyclosporine A kinetics in renal transplant patients. Clin Pharmacol Ther 1987; 41: 221

    Google Scholar 

  75. Grino JM, Sabate I, Casteloa AM, et al. Erythromycin and cyclosporine. Ann Intern Med 1986; 105: 467–8

    PubMed  CAS  Google Scholar 

  76. Gonwa TA, Nghiem DD, Schulak JA, et al. Erythromycin and cyclosporine. Ann Intern Med 1986; 105: 467–8

    Google Scholar 

  77. Murray BM, Edwards L, Morse GD, et al. Clinically important interaction of cyclosporine and erythromycin. Transplantation 1986; 43: 602–4

    Google Scholar 

  78. Lysz K, Rosenberg JC, Kaplan MP, et al. Interaction of erythromycin with cyclosporine. Transpl Proc 1988: 20Suppl. 2: 543–8

    CAS  Google Scholar 

  79. Hourmant M, Le Bigot JF, Vernillet L, et al. Coadministration of erythromycin results in an increase of blood cyclosporine to toxic levels. Transplant Proc 1987; 17: 2723–7

    Google Scholar 

  80. Kessler M, Louis J, Renoult E, et al. Interaction between cyclosporine and erythromycin in a kidney transplant patient. Eur J Clin Pharmacol 1986; 30: 633–4

    PubMed  CAS  Google Scholar 

  81. Kohan DE. Possible interaction between cyclosporine and erythromycin. N Engl J Med 1986; 314: 448

    PubMed  CAS  Google Scholar 

  82. Koselj M, Bren A, Kandus A. Drug interactions between cyclosporine and rifampicin, erythromycin, and azoles in kidney recipients with opportunistic infections. Transplant Proc 1994; 26: 2823–4

    PubMed  CAS  Google Scholar 

  83. Martell R, Heinrichs D, Stiller C, et al. The effects of erythromycin in patients treated with cyclosporine. Ann Intern Med 1986; 104: 660–1

    PubMed  CAS  Google Scholar 

  84. Ptachcinski RJ, Carpenter BJ, Burckart G, et al. Effect of erythromycin on cyclosporine levels. N Engl J Med 1985; 313: 1416–7

    PubMed  CAS  Google Scholar 

  85. Gupta SK, Bakran A, Johnson RWG, et al. Cyclosporin-erythromycin interaction in renal transplant patients. Br J Clin Pharmacol 1989; 27: 475–81

    PubMed  CAS  Google Scholar 

  86. Janssens J, Peeters TL, Vantrappen H, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N Engl J Med 1990; 322: 1028–30

    PubMed  CAS  Google Scholar 

  87. Danan G, Descatoire V, Pessayre D, et al. Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450. J Pharmacol Exp Ther 1981; 218: 509–14

    PubMed  CAS  Google Scholar 

  88. Ben-Ari J, Eisenstein B, Davidovits M, et al. Effect of erythromycin on blood cyclosporine concentrations in kidney transplant patients. J Pediatr 1988; 112: 992–3

    PubMed  CAS  Google Scholar 

  89. Harnett JD, Parfrey PS, Paul MD, et al. Erythromycin-cyclosporine interaction in renal transplant recipients. Transplantation 1987; 43: 316–8

    PubMed  CAS  Google Scholar 

  90. Tripathi A, Panzer MJ. Cyclosporine psychosis. Psychosomatics 1993; 34: 101–2

    PubMed  CAS  Google Scholar 

  91. Moral A, Navasa M, Rimola A, et al. Erythromycin ototoxicity in liver transplant patients. Transplant Int 1994; 7: 62–4

    CAS  Google Scholar 

  92. Sternberg RI, Baughman RP, First MR. Erythromycin-induced hearing loss in immunosuppressed transplant patients. Clin Transplant 1993; 7: 269–72

    Google Scholar 

  93. Azanza JR, Catalan M, Alvarez MP, et al. Possible interaction between cyclosporine and josamycin: a description of three cases. Clin Pharmacol Ther 1992; 51: 572–5

    PubMed  CAS  Google Scholar 

  94. Kreft-Jais C, Billaud EM, Gaudry C, et al. Effect of josamycin on plasma cyclosporine levels. Eur J Clin Pharmacol 1987; 32: 327–8

    PubMed  CAS  Google Scholar 

  95. Herbrecht R, Liu KL, Bergerat JP. Interaction of cyclosporine with antimicrobial agents. Rev Infect Dis 1990; 12: 371

    PubMed  CAS  Google Scholar 

  96. Billaud EM, Guillemain R, Fortineau N, et al. Interaction between roxithromycin and cyclosporin in heart transplant patients. Clin Pharmacokinet 1990; 19: 499–502

    PubMed  CAS  Google Scholar 

  97. Moravek J, Matousovic K, Prat V, et al. Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1990; 28: 262–7

    PubMed  CAS  Google Scholar 

  98. Ferrari SL, Goffin E, Mourad M, et al. The interaction between clarithromycin and cyclosporine in kidney transplant recipients. Transplantation 1994; 58: 725–7

    PubMed  CAS  Google Scholar 

  99. Gersema LM, Porter CB, Russell EH. Suspected drug interaction between cyclosporine and clarithromycin. J Heart Lung Transplant 1994; 13: 343–5

    PubMed  CAS  Google Scholar 

  100. Birmele B, Lebranchu Y, Beliveau F, et al. Absence of interaction between cyclosporine and spiramycin. Transplantation 1989; 47: 927–8

    PubMed  CAS  Google Scholar 

  101. Guillemain R, Billaud E, Dreyfus G, et al. The effects of spiramycin on plasma cyclosporin a concentrations in heart transplantation patients. Eur J Clin Pharmacol 1989; 36: 97–8

    PubMed  CAS  Google Scholar 

  102. Kessler M, Netter P, Renoult E, et al. Lack of effect of spiramycin on cyclosporin pharmacokinetics. Br J Clin Pharmacol 1990; 29: 370–1

    PubMed  CAS  Google Scholar 

  103. Vernillet L, Bertault-Peres P, Berland J, et al. Lack of effect of spiramycin on cyclosporin pharmacokinetics. Br J Clin Pharmacol 1989; 27: 789–94

    PubMed  CAS  Google Scholar 

  104. Gully C, Riem R. Terfenadine-erythromycin-induced torsades de pointes. Ann Med Int 1994; 145(4): 267–8

    Google Scholar 

  105. Honig PK, Woosley RL, Zamani K. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52: 231–8

    PubMed  CAS  Google Scholar 

  106. Fournier P, Pacouret G, Charbonnier B. A new cause for wave burst arrythmia: combination of terfenadine and troleandomycin. Ann Cardiol Angeiol 1993; 42: 249–52

    CAS  Google Scholar 

  107. Honig PK, Wortham DC, Zamani K, et al. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetic and electrocardiographic parameters. Drug Invest 1994; 7: 148–56

    CAS  Google Scholar 

  108. Ahmad SR. USA antihistamine alert. Lancet 1992; 340: 542

    Google Scholar 

  109. Biglin KE, Faraon MS, Constance TD. Drug-induced torsades de pointes: a possible interaction of terfenadine and erythromycin. Ann Pharmacother 1994; 28: 282

    PubMed  CAS  Google Scholar 

  110. Botstein P. Is QT interval prolongation harmful? A regulatory perspective. Am J Cardiol 1993; 72: 50–2

    Google Scholar 

  111. Bryskier A, Agouridas C. Macrolide antibiotics and the heart. Expert Opin Invest Drugs 1994; 3: 1213–9

    Google Scholar 

  112. Cortese LM, Bjornson DC. The new macrolide antibiotics and terfenadine. Ann Pharmacother 1992; 26: 1019

    PubMed  CAS  Google Scholar 

  113. Kemp JP. Decreased antihistamine metabolism. Ann Allergy 1992; 69: 533

    PubMed  CAS  Google Scholar 

  114. Kemp JP. Antihistamines — is there anything safe to prescribe? Ann Allergy 1992; 69: 276–80

    PubMed  CAS  Google Scholar 

  115. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788–90

    PubMed  CAS  Google Scholar 

  116. Stockley I. OTC sales: terfenadine/macrolide interaction. Pharm J 1994; 253: 110

    Google Scholar 

  117. Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532–6

    PubMed  CAS  Google Scholar 

  118. Craft TM. Torsade de pointes after astemizole overdose. BMJ 1986; 292: 660

    PubMed  CAS  Google Scholar 

  119. Hoppu K, Tikanoja T, Tapanaineu P, et al. Accidental astemizole overdose in children. Lancet 1991; 338: 538–40

    PubMed  CAS  Google Scholar 

  120. Tobin JR, Doyle TP, Ackermann AD, et al. Astemizole-induced cardiac conduction disturbances in a child. JAMA 1991; 266: 2737–40

    PubMed  CAS  Google Scholar 

  121. Wiley JF II, Gelber ML, Henretig FM, et al. Cardiotoxic effects of astemizole overdose in children. J Pediatr 1992; 120: 799–802

    PubMed  Google Scholar 

  122. Simons FER, Kesselman MS, Giddins NG, et al. Astemizole-induced torsades de pointes [letter]. Lancet 1988; 2: 624

    PubMed  CAS  Google Scholar 

  123. Snook J, Boothman-Burrele D, Watkins J, et al. Torsade de pointes ventricular tachycardia associated with astemizole overdose. Br J Clin Prac 1988; 42: 257–9

    CAS  Google Scholar 

  124. Warning about astemizole. Lancet 1992; 340: 1155

  125. Zechnich AD, Hedges JR, Eiselt-Proteau D, et al. Possible interactions with terfenadine or astemizole. West J Med 1994; 160: 321–5

    PubMed  CAS  Google Scholar 

  126. Maeda S. Effect of macrolide antibiotics on pharmacokinetics of theophylline. Chemotherapy (Tokyo) 1993; 41: 765–9

    CAS  Google Scholar 

  127. Fuhr U, Staib AH, Kinzig M, et al. Lack of an effect of macrolides on cytochrome P450 1A2 activity in human liver microsomes [abstract no. 206]. Program and abstracts of the First International Conference on the Macrolides, Azalides and Streptogramins; 1992 Jan 22–25; Santa Fe, 47

  128. Prince RA, Wing DS, Weinberger MM, et al. Effect of erythromycin on theophylline kinetics. J Allergy Clin Immunol 1981; 68: 427–31

    PubMed  CAS  Google Scholar 

  129. Ludden TM. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985; 10: 63–79

    PubMed  CAS  Google Scholar 

  130. Lopez-Herce J, Teresa MAG, Beltran AR. Severe theophylline toxicity treated with oral activated charcoal. Intensive Care Med 1991; 17: 244–5

    PubMed  CAS  Google Scholar 

  131. Brazier JL, Kofman J, Faucon G, et al. Retard d’elimination de la theophylline du a la troleandomycine. Absence d’effect de la josamycine. Therapie 1980; 35: 545–9

    PubMed  CAS  Google Scholar 

  132. Fox JL. Infectious asthma treated with triacetyloleandomycin. Pa Med J 1961; 64: 634–5

    PubMed  CAS  Google Scholar 

  133. Kamada AK, Hill MR, Brenner AM. Effect of low-dose troleandomycin on theophylline clearance: implications for therapeutic drug monitoring. Pharmacotherapy 1992; 12: 98–102

    PubMed  CAS  Google Scholar 

  134. Lavarenne J, Paire M, Talon O. Influence d’un nouveau macrolide, la midecamycine, sur les taux sanguins de theophylline. Therapie 1981; 36: 451–6

    PubMed  CAS  Google Scholar 

  135. Spector SL, Katz FH, Farr RS. Troleandomycin: effectiveness in steroid-dependent asthma and bronchitis. J Allergy Clin Immunol 1974; 54: 367–9

    Google Scholar 

  136. Weinberger M, Hudgel D, Spector S, et al. Inhibition of theophylline clearance by troleandomycin. J Allergy Clin Immunol 1977; 59: 228–31

    PubMed  CAS  Google Scholar 

  137. Bandera M, Fioretti M, Rimoldi R, et al. Roxithromycin and controlled release of theophylline, an interaction study. Chemotherapia 1989; 7: 313–6

    Google Scholar 

  138. Hashiguchi K, Niki Y, Soejima R. Roxithromycin does not raise serum theophylline levels. Chest 1992; 102: 653–4

    PubMed  CAS  Google Scholar 

  139. Houin G, Montastruc JL, Lequellec A, et al. A study of interaction of roxithromycin with theophylline. Paper presented at the 5th World Conference on Clinical Pharmacology and Therapeutics; 1992; Yokohama

  140. Niki Y, Nakajima M, Tsukiyama K, et al. Effect of TE-031 (A-56268), a new oral macrolide antibiotic, on serum theophylline concentration. Chemotherapy 1988; 36: 515–20

    Google Scholar 

  141. Siepman N. Influence of clarithromycin on theophylline levels in patients with bronchial infections. Paper presented at the First International Conference on the Macrolides, Azalids, and Streptogramins; 1992 Jan 22–25; Santa Fe

  142. Bartolucci L, Gradoli C, Vincenzi V, et al. Macrolide antibiotics and serum theophylline levels in relation to the severity of respiratory impairment: a comparison between the effects of erythromycin and josamycin. Chemioterapie 1984; 3: 286–90

    CAS  Google Scholar 

  143. Ruff F, Santais MC, Chastagnol D, et al. Macrolide et theophylline: absence d’interaction josamycine-theophylline. Nouv Presse Med 1981; 10: 175

    PubMed  CAS  Google Scholar 

  144. Selles JPh, Pains G, Jaber H, et al. Influence of josamycine on theophylline kinetics. In: Spitzy KH, Karrer L, editors. Proceedings of the 13th International Congress on Chemotherapy: 1983 Aug 28–Sep 2: Vienna. Wien: Egermann Druckereigesellschaft, 1983: 15–20, 36

  145. Barbare JC, Martin F, Biour M. Theophylline overdose and hepatic test anomalies associated with josamycin administration. Therapie 1990; 45: 357–8

    PubMed  CAS  Google Scholar 

  146. Jiménez Baos R, Carro CR, Ubeda MM, et al. Effects of josamycin on serum levels of theophylline. In: Spitzy KH, Karrer L, editors. Proceedings of the 13th International Congress on Chemotherapy: 1983 Aug 28–Sep 2: Vienna. Wien: Egermann Druckereigesellschaft 1983: 5: 36–65

  147. Vallarino G, Merlini M, Vallarino R. Josamicina e teofillinici nella patologia respiratoria pediatrica. G Ital Chemioter 1982; 29Suppl. 1: 129–33

    PubMed  Google Scholar 

  148. Cazzola M, Matera MG, Paternos E, et al. Impact of rokitamycin, a new 16-membered macrolide, on serum theophylline. J Chemother 1991; 3: 240–4

    PubMed  CAS  Google Scholar 

  149. Gardner MJ, Coates PE, Hilligoss DM, et al. Lack of effect of azithromycin on the pharmacokinetics of theophylline in man. Paper presented at the Mediterranean Congress on Chemotherapy; 1992 May 24–29; Athens

  150. Couet W, Ingrand I, Reigner B, et al. Lack of effect of ponsinomycin on the plasma pharmacokinetics of theophylline. Eur J Clin Pharmacol 1989; 37: 101–4

    PubMed  CAS  Google Scholar 

  151. Dal Negro R, Turco P, Pomari C, et al. Miocamycin doesn’t affect theophylline serum levels in COPD patients. Int J Clin Pharmacol Ther Toxicol 1988; 26: 27–9

    Google Scholar 

  152. Principi N, Onorato J, Guiliani MG, et al. Effect of miocamycin on theophylline kinetics in children. Eur J Clin Pharmacol 1987; 31: 701–4

    PubMed  CAS  Google Scholar 

  153. Rimoldi R, Bandera M, Fioretti M, et al. Miocamycin and theophylline blood levels. Chemioterapia 1986: 5: 123–6

    Google Scholar 

  154. Debruyne D, Jehan A, Bigot MC, et al. Spiramycin has no effect on serum theophylline in asthmatic patients. Eur J Clin Pharmacol 1986; 30: 505–7

    PubMed  CAS  Google Scholar 

  155. Bachmann K, Nunlee M, Martin M, et al. Changes in the steady-state pharmacokinetics of theophylline during treatment with dirithromycin. J Clin Pharmacol 1990; 30: 1001–5

    PubMed  CAS  Google Scholar 

  156. Bachmann K, Jaregui L, Sides G. Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin. J Clin Pharmacol 1993; 33: 861–5

    PubMed  CAS  Google Scholar 

  157. Bartkowski R, McDonnell TE. Prolonged alfentanil effect following erythromycin administration. Anaesthesiology 1990; 73: 566–8

    CAS  Google Scholar 

  158. Bartkowski RR, Goldberg ME, Huffnagle S, et al. Sufentanil disposition. Is it affected by erythromycin administration? Anaesthesiology 1993; 78: 260–5

    CAS  Google Scholar 

  159. D’Arcy PF. Interactions with astemizole and terfenadine. Int Pharm J 1993; 7: 53

    Google Scholar 

  160. Christensen LQ, Bonde J, Kampmann JP. Drug interactions with intravenous and local anaesthetics. Acta Anaesth Scand 1994; 38: 15–29

    CAS  Google Scholar 

  161. Bartle WR. Possible warfarin-erythromycin interaction. Arch Intern Med 1980; 140: 985–7

    PubMed  CAS  Google Scholar 

  162. Friedman HW, Bonventre MV. Erythromycin induced digoxin toxicity. Chest 1982; 82: 202

    PubMed  CAS  Google Scholar 

  163. Grau E, Fontcuberta J, Felez J. Erythromycin-oral anticoagulants interaction. Arch Intern Med 1986; 146: 1639

    PubMed  CAS  Google Scholar 

  164. Husserl FE. Erythromycin-warfarin interaction. Arch Intern Med 1983; 143: 1831–6

    PubMed  CAS  Google Scholar 

  165. Sato RI, Gray DR, Brown SE. Warfarin interaction with erythromycin. Arch Intern Med 1984; 144: 2413–4

    PubMed  CAS  Google Scholar 

  166. Schwartz J, Bachmann KA. Erythromycin-warfarin interaction. Arch Intern Med 1984; 144: 2094

    PubMed  CAS  Google Scholar 

  167. Bachmann K, Schwartz JI, Forney Jr R, et al. The effect of erythromycin on the disposition kinetics of warfarin. Pharmacol 1984b; 28: 171–6

    CAS  Google Scholar 

  168. Weibert RT, Lorentz SM, Townsend RJ, et al. Effect of erythromycin in patients receiving long-term warfarin therapy. Clin Pharm 1989; 8: 210–4

    PubMed  CAS  Google Scholar 

  169. Bachmann K. Screening for the influence of host factors on warfarin clearance using a single sample procedure. Int J Clin Pharmacol Ther Toxicol 1986; 24: 167–70

    PubMed  CAS  Google Scholar 

  170. Paulsen O, Nilsson L-G, Saint-Salvi B, et al. No effect of roxithromycin on pharmacokinetic or pharmacodynamic properties of warfarin and its enantiomers. Pharmacol Toxicol 1988; 63: 215–20

    PubMed  CAS  Google Scholar 

  171. Boeckh M, Lode H, Höffken G. Pharmacokinetics of roxithromycin and influences of H2-blockers and antacids on gastrointestinal absorption. Eur J Clin Microbiol Infect Dis 1992; 11: 465–8

    PubMed  CAS  Google Scholar 

  172. Fraschini F, Scaglione F, Demartini G. Clarithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 189–204

    PubMed  CAS  Google Scholar 

  173. Holliday SM, Faulds D. Miocamycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1993; 46: 720–45

    PubMed  CAS  Google Scholar 

  174. Miller LG, Prichard JG, White CA, et al. Effect of concurrent sucralfate administration on the absorption of erythromycin. J Clin Pharmacol 1990; 30: 39–44

    PubMed  CAS  Google Scholar 

  175. Nilson OG. Roxithromycin. A new molecule, a new pharmacokinetic profile. Drug Invest 1991; 3Suppl. 3: 28–32

    Google Scholar 

  176. Lalak NJ, Morris DL. Azithromycin: clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 370–4

    PubMed  CAS  Google Scholar 

  177. Foulds G, Hilligoss DM, Henry EB. The effects of an antacid or cimetidine on the serum concentrations of azithromycin. J Clin Pharmacol 1991; 31: 164–7

    PubMed  CAS  Google Scholar 

  178. Zundorf H, Wischmann L, Fassbender M, et al. Pharmacokinetics of clarithromycin and possible interaction with H2 blockers and antacids [abstract no. 515]. In: Program and Abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; 1991 Oct 1: Chicago. Washington, DC: American Society for Microbiology, 1991: 185

    Google Scholar 

  179. Mogford N, Pallet A, George C. Erythromycin deafness and cimetidine treatment. BMJ 1994; 309: 1620

    PubMed  CAS  Google Scholar 

  180. Nelson MV, Berchou RC, Kareti D, et al. Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine. Clin Pharmacol Ther 1990; 47: 694–7

    PubMed  CAS  Google Scholar 

  181. Janicak PG. The relevance of clinical pharmacokinetics and therapeutic drug monitoring: anticonvulsant mood stabilizers and antipsychotics. J Clin Psychiatry 1993; 54 Suppl.: 35–41

    PubMed  Google Scholar 

  182. Funderberg LG, Vertrees JE, True JE. Seizure following addition of erythromycin to clozapine treatment. Am J Psychiatry 1994; 151: 1840–1

    Google Scholar 

  183. Back DJ, Grimmer SFM, Orme ML’E, et al. Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol 1988; 25: 527–32

    PubMed  CAS  Google Scholar 

  184. Orme M, Back DJ, Tjia J, et al. The lack of interactions between clarithromycin and oral contraceptive steroids. Br J Clin Pharmacol 1991; 31: 229P

    Google Scholar 

  185. Claudel S, Euvrad P, Borx R, et al. Cholestase intrahepatique apres association triacetyloleandomycine-estroprogestif. Nouv Presse Med 1979; 8: 1182–3

    PubMed  CAS  Google Scholar 

  186. Fevery J, van Steenbergen W, Desmet V, et al. Severe intrahepatic cholestasis due to the combined intake of oral contraceptives and triacetyloleandomycin. Acta Clin Belg 1983; 38: 242–5

    PubMed  CAS  Google Scholar 

  187. Haber I, Hubens H. Cholestatic jaundice after triacetyloleandomycin and oral contraceptives: the diagnostic value of gammaglutamyl transpeptidase. Acta Gastroenterol Belg 1980; 43: 475–82

    PubMed  CAS  Google Scholar 

  188. Miguet JP, Vuitton D, Pessayre D, et al. Jaundice from troleandomycin and oral contraceptives. Ann Intern Med 1980; 92: 434

    PubMed  CAS  Google Scholar 

  189. Rollux R, Plottin F, Mingat J, et al. Ictere apres association estroprogestatif-troleandomycine, trois observations. Nouv Presse Med 1979; 8: 1694

    PubMed  CAS  Google Scholar 

  190. Maxwell DL, Gilmour-White SK, et al. Digoxin toxicity due to interaction of digoxin with erythromycin. BMJ 1989; 298: 572

    PubMed  CAS  Google Scholar 

  191. Morton MR, Cooper JW. Erythromycin-induced digoxin toxicity. DICP Ann Pharmacother 1989; 23: 668–70

    CAS  Google Scholar 

  192. Sutton A, Pilot MA. Digoxin toxicity and erythromycin. BMJ 1989; 298: 1101

    PubMed  CAS  Google Scholar 

  193. Lindenbaum J, Rund DG, Butler VP, et al. Inactivation of digoxin by the gut flora: reversible antibiotic therapy. N Engl J Med 1981; 305: 789–94

    PubMed  CAS  Google Scholar 

  194. Ragosta M, Weihl AC, Rosenfeld LE. Potentially fatal interaction between erythromycin and disopyramide. Am J Med 1989; 86: 465–6

    PubMed  CAS  Google Scholar 

  195. Larcan A. L’ergotisme therapeutique. J Pharmacol 1979; 10: 413–30

    Google Scholar 

  196. Boucharlat J, Franco A, Carpentier P, et al. Ergotism aigu par association proprionate d’erythromycine-dihydroergotamine. Nouv Presse Med 1981; 10: 28–30

    Google Scholar 

  197. Dette GA. Wechselwirkungen. In: Wiethoff EO, editor. Erythromycin-Monographie. Wiesbaden: Wissenschaftliche Verlagsabteilung Deutsche Abbott, 1986: 3.1–3.16

    Google Scholar 

  198. Azria M, Kiechel JR, Lavenne D. Contribution à l’étude de l’interaction de la triacetyloléandomycine avec l’ergotamine ou la dihydroergotamine. J Pharmacol 1979; 10: 431–8

    Google Scholar 

  199. Bacourt F, Couffinhal JC. Ischémie des membres par association dihydroergotamine-triacetyloléandomycine. Nouv Presse Med 1978; 7: 1956

    Google Scholar 

  200. Franco A, Boulard P, Masset C, et al. Ergotamine par association dihydroergotamine-triacetyloléandomycine. Nouv Presse Med 1978; 7: 205

    PubMed  CAS  Google Scholar 

  201. Hayton A. Precipitation of acute ergotism by triacetyloleandomycin. N Z Med J 1969; 69: 42

    PubMed  CAS  Google Scholar 

  202. Matthews NT, Havill JH. Ergotism with therapeutic doses of ergotamine tartrate. N Z Med J 1979; 89: 467–7

    Google Scholar 

  203. Liedholm H, Nordin G. Erythromycin-felodipine interaction. DICP Ann Pharmacother 1991; 25: 1007–8

    CAS  Google Scholar 

  204. Fleishaker JC, Phillips JP. Evaluation of a potential interaction between erythromycin and glyburide in diabetic volunteers. J Clin Pharmacol 1991; 31: 259–62

    PubMed  CAS  Google Scholar 

  205. Brion N, Kollenbach K, Marion MH, et al. Effect of a macrolide (spiramycin) on the pharmacokinetics of L-dopa and carbidopa in healthy volunteers. Clin Neuropharmacol 1992; 15: 229–35

    PubMed  CAS  Google Scholar 

  206. Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis [letter]. Ann Intern Med 1988; 109: 682–3

    PubMed  CAS  Google Scholar 

  207. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use — report of two cases in cardiac transplant recipients. JAMA 1988; 260: 239–41

    PubMed  CAS  Google Scholar 

  208. Spach DH, Bauwens JE, Clark CD. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991; 154: 213–5

    PubMed  CAS  Google Scholar 

  209. Itken JH, Menzel ML. The use of macrolide antibiotic substances in the treatment of asthma. J Allergy 1970; 45: 146–62

    Google Scholar 

  210. Kaplan MA, Godin M. The use of triacetyloleandomycin in chronic infectious asthma. In: Welch, Marti-Ibanez, editors. Antibiotics Annual 1958–1959. New York: New York Interscience Publishers, 1959: 273–6

    Google Scholar 

  211. LaForce CF, Szefler SJ, Miller MF, et al. Inhibition of methylprednisolone elimination in the presence of erythromycin therapy. J Allergy Clin Immunol 1983; 72: 34–9

    PubMed  CAS  Google Scholar 

  212. Ziger RS, Schatz M, Sperling W, et al. Efficacy of troleandomycin in outpatients with severe, corticosteroid dependent asthma. J Allegy Clin Immunol 1980; 66: 438

    Google Scholar 

  213. Szefler SJ, Rose JQ, Ellis EF, et al. The effect of troleandomycin on methylprednisolone elimination. J Allergy Clin Immunol 1980; 66: 447–51

    PubMed  CAS  Google Scholar 

  214. Szefler SJ, Brenner M, Jusko WJ, et al. Dose and time related effect of troleandomycin on methylprednisolone elimination. Clin Pharmacol Ther 1982a; 166–71

    Google Scholar 

  215. Szefler SJ, Ellis EF, Brenner M, et al. Steroid-specific anticonvulsion interaction aspects of troleandomycin-steroid therapy. J Allergy Clin Immunol 1982b; 69: 455–60

    PubMed  CAS  Google Scholar 

  216. Baldit C, Vincon G, Bistue C, et al. Influence d’un nouveau macrolide, la dirithromycine, sur la clairance de l’antipyrine. Thérapie 1987; 42: 263–6

    PubMed  CAS  Google Scholar 

  217. Cadot R, Simonet R, Andre P, et al. Absence d’influence de la josamycine sur la pharmacocinetique de l’antipyrine. Therapie 1984; 39: 431–3

    PubMed  CAS  Google Scholar 

  218. Descotes J. Chemical structure and safety of spiramycin. Drug Invest 1993; 6Suppl. 1: 43–8

    Google Scholar 

  219. Bachmann K, Schwartz JI, Fornay Jr R, et al. Single dose Phenytoin clearance during erythromycin treatment. Res Commun Chem Pathol Pharmacol 1984a; 4: 207–17

    Google Scholar 

  220. Burger DM, Meenhorst PL, Mulder JW, et al. Therapeutic drug monitoring of phenytoin in patients with the acquired immunodeficiency syndrome. Ther Drug Monit 1994; 16: 616–20

    PubMed  CAS  Google Scholar 

  221. Gascon MP, Dayer P. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 1991b; 41: 573–8

    PubMed  CAS  Google Scholar 

  222. Krombach T, Mathys D, Umeno M, et al. Oxidation of midazolam and triazolam by human liver cytochrome P-450 III-A4. Mol Pharmacol 1989; 36: 89–96

    Google Scholar 

  223. Phillips JP, Antal EJ, Smith RB. A pharmacokinetic drug interaction between erythromycin and triazolam. J Psychopharmacol 1986; 6: 297–9

    CAS  Google Scholar 

  224. Warot D, Bergougnan L, Lamiable D, et al. Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation. Eur J Clin Pharmacol 1987; 32: 389–93

    PubMed  CAS  Google Scholar 

  225. Gascon MP, Dayer P, Waldvogel F. Les interactions medicamenteuese du midazolam. Schweiz Med Wochenschr 1989; 119: 1834–6

    PubMed  CAS  Google Scholar 

  226. Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993; 53: 298–305

    PubMed  CAS  Google Scholar 

  227. Wood M. Midazolam and erythromycin. Br J Anaesth 1991; 67: 131

    PubMed  CAS  Google Scholar 

  228. Hiller A, Olkkola KT, Isohanni P. Unconsciousness associated with midazolam and erythromycin. Br J Anaesth 1990; 65: 826–8

    PubMed  CAS  Google Scholar 

  229. Narchi P, Benhamou D, Elhaddoury M. Interactions of preoperative erythromycin administration with general anaesthesia. Can J Anaesth 1993; 40: 444–7

    PubMed  CAS  Google Scholar 

  230. Backman JT, Aranko K, Himberg J-J. A pharmacokinetic interaction between roxithromycin and midazolam. Eur J Clin Pharmacol 1994; 46: 551–5

    PubMed  CAS  Google Scholar 

  231. Mattila MJ, Vanakoski J, Idänpään-Heikkilä JJ. Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance. Pharmacol Toxicol 1993; 73: 180–5

    PubMed  CAS  Google Scholar 

  232. Mattila MJ, Vanakoski J, Idänpään-Heikkilä JJ. Azithromycin does not alter the effects of oral midazolam on human performance. Eur J Clin Pharmacol 1994; 47: 49–52

    PubMed  CAS  Google Scholar 

  233. Redington K, Wells C, Petito P. Erythromycin and valproate interaction. Ann Intern Med 1992; 116: 877–8

    PubMed  CAS  Google Scholar 

  234. Chave J-P, Munafo A, Chatton J-Y, et al. Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. Antimicrob Agents Chemother 1992; 36: 1013–8

    PubMed  CAS  Google Scholar 

  235. Polis MA, Haneiwich S, Kovacs JA, et al. Dose escalation study to determine the safety, maximally tolerated dose and pharmacokinetics of clarithromycin with zidovudine in HIV-infected persons [abstract no. 238]. In: Program and Abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy: 1991 Oct 1: Chicago. Washington, DC: American Society for Microbiology, 1991: 138

    Google Scholar 

  236. Pichard L, Fabre I, Fabre G, et al. Screening for inducers and inhibitors of cytochrome P450 (cyclosporine A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos Biol Fate Chem 1990: 18: 595–606

    PubMed  CAS  Google Scholar 

  237. Turgeon DK, Normolle DP, Leichtman AB, et al. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther 1992; 52: 471–8

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Children’s Hospital, Munich, Germany

    Niels-A. von Rosenstiel &  Dieter Adam

Authors
  1. Niels-A. von Rosenstiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dieter Adam
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

von Rosenstiel, NA., Adam, D. Macrolide Antibacterials. Drug-Safety 13, 105–122 (1995). https://doi.org/10.2165/00002018-199513020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199513020-00005

Keywords

Search

Navigation